JP2024530952A5 - - Google Patents

Info

Publication number
JP2024530952A5
JP2024530952A5 JP2024508322A JP2024508322A JP2024530952A5 JP 2024530952 A5 JP2024530952 A5 JP 2024530952A5 JP 2024508322 A JP2024508322 A JP 2024508322A JP 2024508322 A JP2024508322 A JP 2024508322A JP 2024530952 A5 JP2024530952 A5 JP 2024530952A5
Authority
JP
Japan
Application number
JP2024508322A
Other languages
Japanese (ja)
Other versions
JP2024530952A (ja
JPWO2023016434A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/111050 external-priority patent/WO2023016434A1/en
Publication of JP2024530952A publication Critical patent/JP2024530952A/ja
Publication of JPWO2023016434A5 publication Critical patent/JPWO2023016434A5/ja
Publication of JP2024530952A5 publication Critical patent/JP2024530952A5/ja
Pending legal-status Critical Current

Links

JP2024508322A 2021-08-10 2022-08-09 p53変異体を標的とする化合物 Pending JP2024530952A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN2021111797 2021-08-10
CNPCT/CN2021/111797 2021-08-10
CN2021125725 2021-10-22
CNPCT/CN2021/125725 2021-10-22
CNPCT/CN2021/132409 2021-11-23
CN2021132409 2021-11-23
CN2022073977 2022-01-26
CNPCT/CN2022/073977 2022-01-26
CN2022097840 2022-06-09
CNPCT/CN2022/097840 2022-06-09
PCT/CN2022/111050 WO2023016434A1 (en) 2021-08-10 2022-08-09 Compounds targeting mutant of p53

Publications (3)

Publication Number Publication Date
JP2024530952A JP2024530952A (ja) 2024-08-27
JPWO2023016434A5 JPWO2023016434A5 (https=) 2025-06-24
JP2024530952A5 true JP2024530952A5 (https=) 2025-06-24

Family

ID=85199878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508322A Pending JP2024530952A (ja) 2021-08-10 2022-08-09 p53変異体を標的とする化合物

Country Status (15)

Country Link
US (1) US20240400591A1 (https=)
EP (1) EP4384510A4 (https=)
JP (1) JP2024530952A (https=)
KR (1) KR20240062147A (https=)
CN (1) CN117813295A (https=)
AR (1) AR126747A1 (https=)
AU (1) AU2022325357A1 (https=)
CA (1) CA3228559A1 (https=)
CL (1) CL2024000406A1 (https=)
CO (1) CO2024001421A2 (https=)
IL (1) IL310653A (https=)
MX (1) MX2024001870A (https=)
TW (1) TW202322796A (https=)
UY (1) UY39890A (https=)
WO (1) WO2023016434A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
AU2023213949A1 (en) 2022-01-27 2024-07-25 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function
WO2024041503A1 (en) * 2022-08-22 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
TW202435861A (zh) * 2022-12-08 2024-09-16 大陸商北京加科思新藥研發有限公司 靶向p53突變體的化合物
EP4709384A2 (en) * 2023-05-12 2026-03-18 PMV Pharmaceuticals, Inc. Combination therapy for treatment of cancer
EP4727933A1 (en) * 2023-06-19 2026-04-22 Board of Regents, The University of Texas System Combination therapy methods for treating tp53-y220c mutant and tp53 wildtype leukemias
WO2025031471A1 (zh) * 2023-08-09 2025-02-13 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
CN121532383A (zh) * 2023-09-11 2026-02-13 长春金赛药业有限责任公司 p53-Y220C选择性小分子重激活剂化合物、药物组合物及其用途
WO2025082353A1 (en) * 2023-10-16 2025-04-24 Jacobio Pharmaceuticals Co., Ltd. Polymorphic forms of the compounds targeting mutant of p53 and uses thereof
WO2025011684A2 (zh) * 2023-10-20 2025-01-16 上海宇道生物技术有限公司 一类n-磺酰酰胺含氮稠杂环类化合物及其应用
WO2025085725A1 (en) * 2023-10-20 2025-04-24 Scorpion Therapeutics, Inc. Methods for treating a p53-associated cancer
WO2025151449A1 (en) * 2024-01-08 2025-07-17 Photys Therapeutics, Inc. Bifunctional p53-binding compounds and uses thereof
WO2025237199A1 (zh) * 2024-05-11 2025-11-20 上海齐鲁制药研究中心有限公司 含氮并环化合物、含其的药物组合物及其应用
WO2026025042A1 (en) 2024-07-26 2026-01-29 Dana-Farber Cancer Institute, Inc. P53 targeting compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463507A1 (en) * 2001-12-19 2004-10-06 SmithKline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
EP1587781A1 (en) * 2002-11-05 2005-10-26 Eli Lilly And Company 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2015178955A1 (en) * 2014-05-19 2015-11-26 Eternity Bioscience Inc. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
CN109069481A (zh) * 2016-02-19 2018-12-21 皮姆维制药公司 用于恢复突变p53功能的方法和化合物
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
MX2022003456A (es) * 2019-09-23 2022-06-02 Pmv Pharmaceuticals Inc Metodos y compuestos para restaurar la funcion del mutante p53.
IL298549A (en) * 2020-06-24 2023-01-01 Pmv Pharmaceuticals Inc A companion diagnostic tool for compounds reactivating mutant p53
US11938124B2 (en) * 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
US20230049952A1 (en) * 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Similar Documents

Publication Publication Date Title
JP2024530952A5 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
CN307046007S (https=)
CN307048618S (https=)
BY13150U (https=)
CN307049903S (https=)
CN307049664S (https=)
BY13149U (https=)
CN307049626S (https=)
CN307049607S (https=)
BY13152U (https=)
BY13145U (https=)
CN307049484S (https=)
CN307049231S (https=)
BY13144U (https=)
CN307048859S (https=)
CN307048638S (https=)
CN307045257S (https=)
CN307048567S (https=)
CN307048369S (https=)
CN307048271S (https=)
CN307046481S (https=)
BY23963C1 (https=)